GlaxoSmithKline Mercury Limited

GlaxoSmithKline Mercury Limited, headquartered in Great Britain, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, which means that any emissions data or climate commitments would be inherited from its parent organization.

GSK plc has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its own operations (Scope 1 and 2) and by 2045 for its value chain (Scope 3). The specific reduction targets and achievements of GSK plc are cascaded down to GlaxoSmithKline Mercury Limited, ensuring alignment with industry standards and climate action goals.

While GlaxoSmithKline Mercury Limited does not report its own emissions figures, it is committed to following the climate initiatives established by GSK plc, which include participation in the Science Based Targets initiative (SBTi) and other sustainability frameworks. This commitment reflects a proactive approach to addressing climate change and reducing carbon footprints within the pharmaceutical industry.